The global assisted reproductive technology (ART) market is expected to reach USD 45 billion by 2025, according to a new report by Grand View Research, Inc. Childbearing postponement is one of the high impact rendering drivers of the infertility treatment market. The reproductive behavior and pattern of some of the nations such as few European nations have shifted from early to late childbearing pattern.
Increasing marital age, rising tobacco and alcohol consumption, increasing obesity rate are some of the other factors contributing to the market growth. Furthermore, increasing incidence rate of conditions such as poly-cystic ovarian syndrome (PCOS), tubal factors and endometriosis are other drivers of the market.
Request A Sample Copy Of This Report @: https://www.radiantinsights.com/research/assisted-reproductive-technology-art-market/request-sample
According to the Society for Assisted Reproductive Technology, 2012 was the year with highest percentage of babies born through IVF treatment. The treatment has become more successful and has gained more acceptance, which is further expected to increase the market size in the coming years.
Further key findings from the report suggest:
• Fresh non-donor was the largest ART market procedure segment in 2014. The fact that fresh eggs and sperms increase the number of successful pregnancies is expected to drive segment growth over the forecast period.
• According to a recent study published in the New England Journal of Medicine.bythe researchers from Vietnam and China, frozen embryos are not more effective in comparison to the fresh embryos for all women, specifically those suffering from PCOS.
• Frozen non-donor is identified as the most lucrative procedure segment of the assisted reproductive technology industry. A new study claims that the fertility treatment with frozen embryos may have more probability of success than those performed with fresh embryos.
• IVF with ICSI dominated the technology type market segment owing to increase in the chances of successful fertilization, and exceptional technique for treating male infertility. As per the study published in fertility journal Human Reproduction Update 2017, North America, Europe, New Zealand and Australia, men's sperm counts declined by 50-60% over the period between 1973 and 2011. Changing lifestyle and environmental factors are some of the factors responsible for the decline of sperm counts.
• Frozen embryo replacement (FER) is anticipated to grow at a rapid rate over the forecast period owing to the fact that in the clinics fresh embryos are used first and only good quality and spare embryos are transferred at a later stage. The trend is to transfer single embryos rather than risking by transferring two or more embryos. This is expected to increase the FER segment market in the coming years.
• Europe dominated the market and is anticipated to maintain its dominance during the forecast period The Asia Pacific region is likely to witness significant growth over the next decade due to improving healthcare infrastructure, increasing awareness and adoption of IVF procedures.
• Technological advancements is expected to drive the market in the coming years. In 2016, INVO Bioscience, Inc. announced the FDA approval of first intravaginal culture system, INVOcell, wherein women's vagina is used as a natural incubator and the clinical trials have produced pregnancy similar to traditional IVF treatments
• Some of the key players are California Cryobank, Bloom IVF Centre, Parallabs, OvaScience, Anecova, Origio, Microm Ltd., Merck KGaA, Ferring Pharmaceuticals, Boston Science Corporation and Hamilton Throne Ltd.
• Fresh non-donor was the largest ART market procedure segment in 2014. The fact that fresh eggs and sperms increase the number of successful pregnancies is expected to drive segment growth over the forecast period.
• According to a recent study published in the New England Journal of Medicine.bythe researchers from Vietnam and China, frozen embryos are not more effective in comparison to the fresh embryos for all women, specifically those suffering from PCOS.
• Frozen non-donor is identified as the most lucrative procedure segment of the assisted reproductive technology industry. A new study claims that the fertility treatment with frozen embryos may have more probability of success than those performed with fresh embryos.
• IVF with ICSI dominated the technology type market segment owing to increase in the chances of successful fertilization, and exceptional technique for treating male infertility. As per the study published in fertility journal Human Reproduction Update 2017, North America, Europe, New Zealand and Australia, men's sperm counts declined by 50-60% over the period between 1973 and 2011. Changing lifestyle and environmental factors are some of the factors responsible for the decline of sperm counts.
• Frozen embryo replacement (FER) is anticipated to grow at a rapid rate over the forecast period owing to the fact that in the clinics fresh embryos are used first and only good quality and spare embryos are transferred at a later stage. The trend is to transfer single embryos rather than risking by transferring two or more embryos. This is expected to increase the FER segment market in the coming years.
• Europe dominated the market and is anticipated to maintain its dominance during the forecast period The Asia Pacific region is likely to witness significant growth over the next decade due to improving healthcare infrastructure, increasing awareness and adoption of IVF procedures.
• Technological advancements is expected to drive the market in the coming years. In 2016, INVO Bioscience, Inc. announced the FDA approval of first intravaginal culture system, INVOcell, wherein women's vagina is used as a natural incubator and the clinical trials have produced pregnancy similar to traditional IVF treatments
• Some of the key players are California Cryobank, Bloom IVF Centre, Parallabs, OvaScience, Anecova, Origio, Microm Ltd., Merck KGaA, Ferring Pharmaceuticals, Boston Science Corporation and Hamilton Throne Ltd.
Browse Full Research Report With TOC @: https://www.radiantinsights.com/research/assisted-reproductive-technology-art-market
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment